As­traZeneca makes an­oth­er car­dio deal, bet­ting $100M on Chi­na com­pa­ny’s lipid drug

As­traZeneca is strength­en­ing its car­dio­vas­cu­lar dis­ease pipeline with a $100 mil­lion up­front deal for a lipid-tar­get­ing drug from Chi­na’s CSPC Phar­ma­ceu­ti­cal Group.

The UK drug­mak­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER